VRTXVertex Pharmaceuticals

Each row is one issuer’s token for Vertex Pharmaceuticals, with the chains it is deployed on. A bold chain is one where these wallets hold a balance. Tokens are not shares: no issuer in the registry publishes a shares-per-token ratio, so a balance is counted one per share and marked where that assumption is doing work.

Tokenized versions of Vertex Pharmaceuticals, the issuer behind each, the chains it is deployed on, and what these wallets hold of it.

Token	Issuer	Chains	You hold
VRTXon	Ondo	ETHBNBSOL	—
rVRTX	Reality	ARBMRPH	—
VRTXx	xStocks	SOLTON

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Type

Common stock

Sector

Healthcare › Biotechnology

Exchange

Nasdaq

Listed since

Jul 31, 1991

Shares outstanding

253.81M

Employees

6,400

As the market data provider names it. Where that differs from the issuers’ name for the security, both are shown so the difference is visible.